Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Multiparametric Lung MRI With Diffusion-Weighted Imaging in Lung-RADS 4 Lesion Characterization

17. srpna 2026 aktualizováno: University of Florida

Multiparametric Lung MRI With Diffusion-Weighted Imaging in Lung-RADS 4 Lesion Characterization: A Single-Center Prospective Diagnostic Accuracy Study

This study evaluates whether multiparametric chest magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI), performed without any contrast material, can distinguish malignant from benign lung lesions that were assigned Lung-RADS category 4 on a standard-of-care lung cancer screening low-dose CT.

Participants who have a Lung-RADS 4 lesion on screening CT undergo one non-contrast research MRI of the chest at 3.0 Tesla. The MRI is added to standard care; no standard-of-care imaging, biopsy, or treatment is withheld or replaced, and the research MRI is not used for clinical decision making. Participants then continue routine clinical management, and the final nature of the lesion is established from pathology or microbiology when tissue is obtained, or otherwise from at least 24 months of clinical and imaging follow-up.

The primary measure is the sensitivity and specificity of multiparametric MRI against that final diagnosis. Secondary measures include whether DWI alone performs as well as the full MRI protocol, how MRI compares with PET/CT in participants who had PET/CT as part of their care, and quantitative MRI thresholds (apparent diffusion coefficient, lesion-to-spinal-cord signal intensity ratio, native T1 and T2).

This is an exploratory pilot and feasibility study. No formal power calculation was performed; the sample size is intended to support feasibility assessment, protocol optimization, and preliminary estimates of diagnostic performance.

Přehled studie

Detailní popis

OBJECTIVES

Aim 1. Determine the sensitivity and specificity of multiparametric chest MRI with DWI in differentiating malignant from benign Lung-RADS 4 lesions.

Aim 2. Determine whether DWI alone is as effective as the full chest protocol in malignancy classification of Lung-RADS 4 lesions.

Aim 3. Compare the diagnostic performance of chest MRI to PET/CT in the characterization of Lung-RADS 4 lesions.

DESIGN

Single-center prospective observational cohort study of diagnostic accuracy at the University of Florida. Participants identified from the institutional lung cancer screening program with a Lung-RADS 4 (4A, 4B, 4X) finding on standard-of-care low-dose CT undergo one non-contrast research chest MRI. There is no randomization and no comparator group; the comparator is the reference standard (final clinical diagnosis) and, for Aim 3, the participant's standard-of-care PET/CT where performed.

INDEX TEST

All examinations are performed on a 3.0 Tesla scanner (GE Healthcare or Siemens Healthineers) with a vendor-specific surface coil; an interlocking neck coil may be added to the torso coil for apical lesions. No intravenous or other contrast material is administered. Sequences comprise axial breath-hold 2D in- and opposed-phase gradient echo T1-weighted imaging; axial breath-hold and/or respiratory-triggered DWI using multi-shot fat-suppressed echo-planar imaging with two b values; DWI sequences with restricted z-axis coverage centered on the nodule (EPI-DWI, FOCUS/ZOOMit-EPI, MUSE/RESOLVE); and axial respiratory-triggered T2-weighted imaging with fat suppression or Dixon. Ultra-short echo time imaging and T1/T2 mapping centered on the nodule may be added if time allows. Pulse-sequence parameters are optimized to the vendor platform during a pre-clinical optimization phase and after the first participants are scanned.

IMAGE ANALYSIS

Anonymized MRI examinations are read independently by two cardiothoracic radiologists with more than 5 years of MRI experience. Readers have the companion low-dose CT but are blinded to clinical data and to any additional imaging. Reading proceeds in two rounds: DWI alone in conjunction with the LDCT (Aim 2), then the full set of sequences (Aim 1). Each examination is classified as (1) negative / low suspicion for malignancy, (2) indeterminate, would benefit from short-term follow-up, or (3) positive / high suspicion for malignancy. Quantitative measures are the apparent diffusion coefficient from a circular or elliptical ROI over the lowest-signal component of the nodule, and the nodule-to-spinal-cord signal intensity ratio measured at the same level.

REFERENCE STANDARD

The final etiology of the lesion is determined by histopathological and/or microbiological data when available, or otherwise by imaging and clinical follow-up for at least 24 months. A lesion that disappears or decreases in size on follow-up is deemed benign; a lesion that remains stable for at least 24 months is deemed benign.

STATISTICAL ANALYSIS

Sensitivity and specificity of chest MRI and of DW-MRI alone are reported with 95% confidence intervals, computed both excluding and including indeterminate examinations. For participants whose standard-of-care PET/CT was performed within a 3-week interval, sensitivity and specificity of the two modalities are compared pairwise by McNemar's test. Thresholds for ADC, lesion-to-spinal-cord ratio, native T1 and T2 are explored by ROC analysis at Youden's index. Interobserver agreement is assessed by kappa for categorical variables and intraclass correlation for continuous variables. Analyses are performed in R version 4.4.1 or higher at a significance level of 0.05. No interim analysis is planned.

Typ studie

Pozorovací

Zápis (Odhadovaný)

30

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Bruno Hochhegger, MD PHD
  • Telefonní číslo: (352) 265-0291
  • E-mail: bhochhegger@ufl.edu

Studijní záloha kontaktů

Studijní místa

    • Florida
      • Gainesville, Florida, Spojené státy, 32610
        • UF Health Shands Hospital
        • Kontakt:
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Adults aged 50 to 80 years enrolled in the University of Florida lung cancer screening program who meet 2021 USPSTF screening eligibility (at least a 20 pack-year smoking history, currently smoking or quit within the past 15 years) and whose standard-of-care screening low-dose chest CT was assigned Lung-RADS category 4 (4A, 4B, or 4X). Participants are identified consecutively from institutional lung cancer screening CT reports and approached through a treating clinician who is a listed investigator, or through the UF Consent2Share registry.

Popis

Inclusion Criteria:

  1. Age 50 to 80 years, inclusive.
  2. At least a 20 pack-year cigarette smoking history, and currently smoking or quit within the past 15 years (2021 USPSTF lung cancer screening eligibility).
  3. Underwent a standard-of-care lung cancer screening low-dose chest CT (LDCT) at the University of Florida that was assigned Lung-RADS category 4 (4A, 4B, or 4X) per ACR Lung-RADS v2022.
  4. Able to provide written informed consent independently.

Exclusion Criteria:

  1. Part-solid or cystic nodule with a solid component measuring less than 8 mm.
  2. Endobronchial nodule.
  3. MRI-incompatible or potentially MRI-incompatible implanted device.
  4. Claustrophobia that would prevent the participant from tolerating the MRI examination.
  5. Metallic device in the chest wall or spine that may interfere with adequate image acquisition in the field of view (assessed case by case).
  6. History of prior lung resection for a benign condition that may create susceptibility artifact in the field of view.
  7. Home oxygen supplementation.
  8. Active or treated lower respiratory tract infection within the prior 4 weeks.
  9. Lack of capacity to consent.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Lung-RADS 4 lesion on screening LDCT
Adults aged 50-80 who meet 2021 USPSTF lung cancer screening criteria and have a Lung-RADS category 4 (4A, 4B, or 4X) lesion on a standard-of-care lung cancer screening low-dose chest CT. Each participant undergoes one non-contrast multiparametric chest MRI at 3.0 T for research purposes, in addition to standard of care. No standard-of-care imaging, biopsy, or treatment is withheld or replaced, and the research MRI is not used for clinical decision making. Participants continue routine clinical management; the final nature of the lesion is established from histopathology or microbiology when tissue is obtained, or otherwise from at least 24 months of clinical and imaging follow-up.
Single non-contrast chest MRI on a 3.0 Tesla scanner (GE Healthcare or Siemens Healthineers) with a vendor-specific surface coil. Sequences: axial breath-hold 2D in- and opposed-phase gradient echo T1-weighted imaging; axial breath-hold and/or respiratory-triggered multi-shot fat-suppressed EPI DWI with two b values; reduced-FOV DWI centered on the nodule; axial respiratory-triggered T2-weighted imaging with fat suppression or Dixon. Optional UTE and T1/T2 mapping if time allows. No intravenous or other contrast material is administered.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Sensitivity and specificity of multiparametric chest MRI for malignancy in Lung-RADS 4 lesions
Časové okno: From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Sensitivity and specificity, each with a 95% confidence interval, of the reader classification of multiparametric chest MRI (full protocol) for malignant versus benign lesion, against the final clinical diagnosis as the reference standard. Reported both excluding and including examinations classified as indeterminate, to determine whether indeterminate examinations are better grouped with low or with high suspicion.
From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Sensitivity and specificity of diffusion-weighted imaging alone
Časové okno: From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Sensitivity and specificity with 95% confidence intervals of the reader classification based on DWI alone read in conjunction with the companion low-dose CT (round 1), against the final clinical diagnosis, for comparison with the full-protocol estimates (Aim 2).
From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Diagnostic performance of chest MRI compared with PET/CT
Časové okno: From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Sensitivity and specificity of chest MRI and of standard-of-care PET/CT compared pairwise by McNemar's test, in the subset of participants whose PET/CT was performed within a 3-week interval (Aim 3). PET/CT is standard of care and is not scheduled by the study.
From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Apparent diffusion coefficient (ADC) threshold for malignancy
Časové okno: From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Optimal ADC threshold identified by ROC analysis at Youden's index, with the sensitivity, specificity and 95% confidence intervals at that threshold. ADC is measured from a circular or elliptical region of interest placed over the lowest-signal component of the nodule, avoiding artifact, with correlation to the low-dose CT.
From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Lesion-to-spinal-cord signal intensity ratio (LSR) threshold for malignancy
Časové okno: From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Optimal LSR threshold by ROC analysis at Youden's index with sensitivity, specificity and 95% confidence intervals. LSR is calculated from the signal intensity of the nodule and of the spinal cord measured at the same level.
From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Native T1 and T2 thresholds for malignancy
Časové okno: From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Optimal native T1 and T2 thresholds by ROC analysis at Youden's index, with sensitivity, specificity and 95% confidence intervals at each threshold, in participants for whom T1 and T2 mapping centered on the nodule was acquired.
From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Diagnostic performance of a short (<10 minute) acquisition protocol
Časové okno: From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Sensitivity and specificity of the abbreviated acquisition (a single diffusion sequence with restricted z-axis coverage centered on the nodule, acquisition time under 10 minutes) compared with the full protocol, to assess whether the short protocol is non-inferior.
From the research MRI to establishment of the final diagnosis: histopathology or microbiology when tissue is obtained, otherwise at least 24 months of clinical and imaging follow-up per participant.
Feasibility: prevalence of eligible patients and conversion of eligible patients to enrolled participant
Časové okno: Through the enrollment period, up to 24 months from study start.
Number of Lung-RADS 4 examinations screened, number meeting all eligibility criteria, and number enrolled and scanned, yielding the prevalence of eligible patients in the UF lung cancer screening population and the eligible-to-enrolled conversion rate. Stated in the source protocol as an explicit goal the sample size is intended to support.
Through the enrollment period, up to 24 months from study start.
Interobserver agreement between the two readers
Časové okno: At completion of image interpretation, after both reading rounds are finished for all enrolled participants. Up to 48 months from study start.
Agreement between the two independent cardiothoracic radiologists: Cohen's kappa for the three-category suspicion classification and intraclass correlation coefficients for continuous measures (ADC, LSR, T1, T2). Interpreted as 0.01-0.20 minor, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 high, 0.81-1.00 excellent.
At completion of image interpretation, after both reading rounds are finished for all enrolled participants. Up to 48 months from study start.
Prevalence of each MRI suspicion category
Časové okno: At completion of image interpretation, after both reading rounds are finished for all enrolled participants. Up to 48 months from study start.
Proportion of examinations classified into each of the three reader categories: (1) negative / low suspicion for malignancy, (2) indeterminate, would benefit from short-term follow-up, (3) positive / high suspicion for malignancy.
At completion of image interpretation, after both reading rounds are finished for all enrolled participants. Up to 48 months from study start.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. ledna 2027

Primární dokončení (Odhadovaný)

1. ledna 2031

Dokončení studie (Odhadovaný)

1. ledna 2032

Termíny zápisu do studia

První předloženo

12. srpna 2026

První předloženo, které splnilo kritéria kontroly kvality

12. srpna 2026

První zveřejněno (Aktuální)

17. srpna 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

19. srpna 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

17. srpna 2026

Naposledy ověřeno

1. srpna 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit